Doxa AB (DOXA) AI Stock Analysis

• Market Cap: kr613.84M
• Dividend Yield: N/A
• Average Volume (3M): 935.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: 3.57%
• EPS Growth: -925.35%
• Country: SE
• Employees: 5
• Sector: Consumer Defensive
• Sector Strength: 51
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.10
• Shares Outstanding: 1,285,530,600
• 10 Day Avg. Volume: 1,311,431
• 30 Day Avg. Volume: 935,415
• PEG Ratio: -0.01
• Price to Book (P/B): 0.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr0.45
• Price Target Upside: -6.86% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: kr0.50 ▲(4.17%Upside)

Doxa AB's overall stock score is heavily impacted by its weak financial performance and poor valuation metrics, which reflect significant ongoing challenges. Although technical analysis indicates short-term positive momentum, the underlying financial instability poses a considerable risk for investors. The lack of earnings call insights and corporate events does not alter this assessment.

Doxa AB Business Overview & Revenue Model

Company Description

Doxa AB (DOXA) is a Sweden-based company that operates primarily in the dental and medical technology sectors. The company specializes in the development, manufacturing, and marketing of biomaterials used in dental care. Doxa's flagship product, Ceramir, is a dental cement known for its innovative properties, including ease of use and biocompatibility, which are highly valued in the dental industry.

How the Company Makes Money

Doxa AB generates revenue through the sale of its dental products, particularly the Ceramir range of dental cements. The company markets its products to dental professionals and clinics, leveraging a network of distributors to reach a global market. In addition to direct sales, Doxa may engage in partnerships with dental product distributors and manufacturers, enhancing its market reach and distribution capabilities. The company's earnings are influenced by its ability to innovate and meet the evolving needs of the dental industry, as well as its strategic relationships with key industry players.

Doxa AB Financial Statement Overview

Summary

Doxa AB exhibits significant financial challenges, with negative net income, declining EBIT, and persistent negative cash flows. The balance sheet is strained by rising debt levels, increasing financial risk despite a strong equity ratio.

Income Statement

Doxa AB's income statement highlights significant challenges, with consistent negative net income and declining EBIT over the years. The company has not been able to maintain profitability, evidenced by negative EBIT and EBITDA margins, especially in the TTM period. Revenue growth is volatile, with recent declines indicating further instability in financial performance.

Balance Sheet

While Doxa AB has a relatively high level of stockholders' equity compared to its total assets, indicating a strong equity ratio, the increasing level of debt over recent periods raises leverage concerns. The debt-to-equity ratio has worsened, suggesting higher financial risk. Stability is mitigated by significant liabilities and declining asset values.

Cash Flow

The cash flow statement reveals persistent negative operating cash flows and free cash flows, indicating cash management issues. The free cash flow growth rate is negative, showing a lack of improvement in cash flow generation. Additionally, the operating cash flow to net income ratio indicates inefficiency in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.50M	9.90M	5.20M	10.90M	8.54M
Gross Profit	-540.60M	9.90M	-35.60M	7.90M	8.40M
EBITDA	-1.70B	296.00M	-39.80M	77.20M	-12.20M
Net Income	-1.72B	291.90M	-33.00M	76.20M	-13.69M
Balance Sheet
Total Assets	8.20B	3.50B	1.79B	878.80M	14.48M
Cash, Cash Equivalents and Short-Term Investments	70.60M	111.90M	60.00M	15.10M	4.58M
Total Debt	3.63B	9.70M	4.90M	0.00	0.00
Total Liabilities	5.89B	280.80M	18.30M	9.00M	5.04M
Stockholders Equity	2.31B	3.22B	1.77B	869.80M	9.44M
Cash Flow
Free Cash Flow	-63.60M	-37.80M	-39.40M	-18.60M	-15.66M
Operating Cash Flow	-63.20M	-37.80M	-38.50M	-18.60M	-14.28M
Investing Cash Flow	-834.90M	-205.10M	-267.30M	-392.90M	-1.34M
Financing Cash Flow	807.70M	294.70M	350.70M	422.10M	15.53M

Doxa AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DOXA, the sentiment is Positive. The current price of 0.48 is above the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.44, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.14 is Neutral, neither overbought nor oversold. The STOCH value of 87.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:DOXA.

Doxa AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.19B	46.07	7.87%	―	-10.34%	-59.69%
INTEG.B	62 Neutral	kr888.57M	―	-19.17%	―	-12.50%	-783.92%
Sector *	62 Neutral	kr23.48B	14.12	52.46%	4.26%	7.91%	-20.51%
SEDANA	60 Neutral	kr1.47B	―	-5.40%	―	16.27%	-22.61%
BRAIN	50 Neutral	kr382.11M	―	-33.54%	―	72.05%	33.68%
DOXA	49 Neutral	kr613.84M	―	-51.41%	―	3.57%	-925.35%
MNTC	46 Neutral	kr356.69M	―	-45.57%	―	-6.82%	-449.87%